0
Abstract: Poster Presentations |

TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS SOLELY WITH ANTI-ACID GASTRO-ESOPHAGEAL REFLUX THERAPY: A CASE SERIES OF FOUR PATIENTS WITH LONG-TERM FOLLOW-UP FREE TO VIEW

Ganesh Raghu, MD; Steve T. Yang, MBBS*; Carolyn Spada, RN; Jennifer Hayes, RN; Carlos Pelligrini, MD
Author and Funding Information

Singapore General Hospital, Singapore, Singapore


Chest


Chest. 2005;128(4_MeetingAbstracts):316S-b-317S. doi:10.1378/chest.128.4_MeetingAbstracts.316S-b
Text Size: A A A
Published online

Abstract

PURPOSE:  Idiopathic pulmonary fibrosis (IPF) is a relentless, progressive and fatal disease with no known effective treatment. Increased acid gastro-esophageal reflux (GER) has been associated with IPF. We speculate that acid gastroesophageal reflux (GER) is an important factor for the development and/or progression of IPF.

METHODS:  Patients with new onset IPF and presenting with symptoms and documented gastro-esophageal reflux disease (GERD) or abnormal acid GER by 24-hour esophageal pH probe testing, who refused conventional therapy (prednisone and azathioprine) or other concurrent medical treatments implicated for IPF and chose to be treated solely with anti-acid GER therapy.

RESULTS:  Adequate suppression of acid GER was ascertained by 24-hour esophageal pH monitoring. Patients were followed regularly with pulmonary function tests (PFT) over 2-6 years. The PFTs (Forced vital capacity [FVC] and diffusion capacity for carbon monoxide [DLCO]) in all 4 patients stabilised or improved while being maintained on adequate daily treatment for acid GER, and were alive at last follow-up. None of the patients manifested acute exacerbation of IPF nor needed additional treatment for respiratory problems or antibiotics during this period. After maintaining 4 years of improved status in PFTs and exercise testing while adhering to treatment for acid GER, one patient’s deterioration correlated with poor compliance to daily treatment during the 5th year, although the PFTs at last follow-up 6 years since diagnosis showed stabilisation compared to baseline. Another patient stabilised upon adhering to anti-acid GER treatment after an initial period of deterioration that was associated with non-adherence.

CONCLUSION:  This case series suggests that acid GER might be an important risk factor for IPF progression and that adequate treatment for abnormal acid GER may in part improve the outcome of patients with IPF. We also hypothesize that pulmonary fibrosis occurs in individuals who are genetically susceptible to develop fibrosis from recurrent chronic acid GER.

CLINICAL IMPLICATIONS:  Future clinical studies are indicated to determine the efficacy of treatment for acid GER in IPF either in combination with other agents or as a sole agent.

DISCLOSURE:  Steve Yang, None.

Wednesday, November 2, 2005

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543